Assenagon Asset Management S.A. Grows Stock Position in Lantheus Holdings, Inc. $LNTH

Assenagon Asset Management S.A. increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 83.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 132,319 shares of the medical equipment provider’s stock after acquiring an additional 60,376 shares during the period. Assenagon Asset Management S.A.’s holdings in Lantheus were worth $10,036,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LNTH. Smartleaf Asset Management LLC grew its position in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in Lantheus in the second quarter valued at approximately $36,000. Parallel Advisors LLC lifted its position in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Lantheus during the fourth quarter valued at approximately $39,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of LNTH stock opened at $109.80 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $111.46. The firm has a market cap of $7.15 billion, a P/E ratio of 26.46 and a beta of -0.03. The business’s 50 day moving average price is $95.88 and its 200-day moving average price is $80.00.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the prior year, the company earned $1.53 earnings per share. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Truist Financial reissued a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Citizens Jmp boosted their price objective on shares of Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. Finally, Mizuho upped their price objective on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.